Skip to main content

Advertisement

SpringerLink
Log in

Clinical Overview of Cutaneous Features in Hypereosinophilic Syndrome

  • Invited Commentary
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

The hypereosinophilic syndromes (HES) are a heterogeneous group of disorders defined as persistent and marked blood eosinophilia of unknown origin with systemic organ involvement. HES is a potentially severe multisystem disease associated with considerable morbidity. Skin involvement and cutaneous findings frequently can be seen in those patients. Skin symptoms consist of angioedema; unusual urticarial lesions; and eczematous, therapy-resistant, pruriginous papules and nodules. They may be the only obvious clinical symptoms. Cutaneous features can give an important hint to the diagnosis of this rare and often severe illness. Based on advances in molecular and genetic diagnostic techniques and on increasing experience with characteristic clinical features and prognostic markers, therapy has changed radically. Current therapies include corticosteroids, hydroxyurea, interferon-α, the tyrosine kinase inhibitor imatinib mesylate, and (in progress) the monoclonal anti–interleukin-5 antibodies. This article provides an overview of current concepts of disease classification, different skin findings, and therapy for HES.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Griffin H. Persistant eosinophilia with hyperleucocytosis and splenomegaly. Am J Med Sci. 1919;158:618–29.

    Google Scholar 

  2. Hardy WR, Anderson R. The hypereosinophilic syndrome. Ann Intern Med Sci. 1968;158:618–29.

    Google Scholar 

  3. Weller PF. Eosinophils: structure and functions. Curr Opin Immunol. 1994;6:85–91.

    Article  PubMed  CAS  Google Scholar 

  4. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–79.

    PubMed  CAS  Google Scholar 

  5. Spry CJ. The hypereosinophilic syndrome: clinical features, laboratory findings and treatment. Allergy. 1982;37(8):539–51.

    Article  PubMed  CAS  Google Scholar 

  6. Weller PF, Dvorak AM. The idiopathic hypereosinophilic syndrome. Arch Dermatol. 1996;132:583–5.

    Article  PubMed  CAS  Google Scholar 

  7. Gleich GJ, Schroeter AL, Marcoux P, et al. Episodic angioedema associated with eosinophilia. N Engl J Med. 1984;310:1621–6.

    Article  PubMed  CAS  Google Scholar 

  8. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):333–55.

    Article  PubMed  Google Scholar 

  9. Chusid MJ, Dale CD, West BC. The hypereosinophilic syndrome: analysis of 14 cases with review of the literature. Medicine. 1975;54:1–27.

    Article  PubMed  CAS  Google Scholar 

  10. Sheikh J, Weller PF. Advances in diagnosis &treatment of eosinophilia. Curr Opin Hematol. 2009;16(1):3–8.

    Article  PubMed  Google Scholar 

  11. Schwartz LB, Sheikh J, Singh A. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Curr Med Res Opin. 2010;26(8):1933–46.

    Article  PubMed  CAS  Google Scholar 

  12. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, Rosenwasser LJ, Roufosse F, Gleich GJ, Klion AD. Refining the definition of hypereosinophilic syndrome. JACI. 2010;126(1):45–9.

    Google Scholar 

  13. Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med. 2006;27:158–70.

    Article  PubMed  Google Scholar 

  14. Ring J. Allergy in practice. New York: Springer Berlin; 2005.

    Google Scholar 

  15. Ring J, Ruzicka T, Przybilla B, editors. Handbook of atopic eczema. 2nd ed. New York: Springer Berlin; 2006.

    Google Scholar 

  16. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003;54:169–84.

    Article  PubMed  CAS  Google Scholar 

  17. Roufosse F, Cogan E, Goldman M. Recent advances in the pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004;59:673–89.

    Article  PubMed  CAS  Google Scholar 

  18. Roufosse F, Cogan E, Goldman M. Lymphocytic variant of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):389–413.

    Article  PubMed  Google Scholar 

  19. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112–20.

    Article  PubMed  CAS  Google Scholar 

  20. Plötz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349(24):2334–9.

    Article  PubMed  Google Scholar 

  21. Cools J, De Angelo D, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGRA and FIP1L1 genes as therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–14.

    Article  PubMed  CAS  Google Scholar 

  22. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101(12):4660–6.

    Article  PubMed  CAS  Google Scholar 

  23. Klion AD, Bochner BS, Gleich GJ, et al. The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117(6):1292–302.

    Article  PubMed  Google Scholar 

  24. Reiter A, Grimwade D, Cross NC. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica. 2007;92(9):1153–8.

    Article  PubMed  Google Scholar 

  25. Reiter A, Inverbizzi R, Cross NC, Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2009;94(12):1634–8.

    Article  PubMed  CAS  Google Scholar 

  26. Gleich GF, Leifermann KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–8.

    Article  PubMed  CAS  Google Scholar 

  27. Valent P. Pathogenesis, classification and therapy of eosinophilia and eosinophilic disorders. Blood Rev Med. 2003;23:157–65.

    Article  CAS  Google Scholar 

  28. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukaemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82–5.

    Article  PubMed  Google Scholar 

  29. Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol. 2004;113(1):50–8.

    Article  PubMed  Google Scholar 

  30. Leiferman KM, O’Duffy JD, Perry HO, et al. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA. 1982;247(7):1018–20.

    Article  PubMed  CAS  Google Scholar 

  31. Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):415–41.

    Article  PubMed  Google Scholar 

  32. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215–28.

    Article  PubMed  CAS  Google Scholar 

  33. Sanderson CJ. Pharmacological implications of interleukin-5 in the control of eosinophilia. Adv Pharmacol. 1992;23:163–77.

    Article  PubMed  CAS  Google Scholar 

  34. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101–9.

    PubMed  CAS  Google Scholar 

  35. Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535–8.

    Article  PubMed  CAS  Google Scholar 

  36. Simon HU, Yousefi S, Dommann-Scherrer C, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med. 1996;183:1071–82.

    Article  PubMed  CAS  Google Scholar 

  37. Roufosse F, Schadene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Hematol. 2000;109:540–8.

    Article  CAS  Google Scholar 

  38. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica. 2009;94:1236–41.

    Article  PubMed  CAS  Google Scholar 

  39. Plötz SG, Dibbert B, Abeck D, et al. Bcl-2 expression by eosinophils in a patient with hypereosinophilia. J Allergy Clin Immunol. 1998;102:1037–40.

    Article  PubMed  Google Scholar 

  40. Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica. 2009;94:1188–93.

    Article  PubMed  CAS  Google Scholar 

  41. Spry CJ, Kay AB, Gleich GJ. Eosinophils. Immunol Today. 1992;13:384–7.

    Article  PubMed  CAS  Google Scholar 

  42. Plotz SG, Abeck D, Seitzer U, Hein R, Ring J. UVA1 for hypereosinophilic syndrome. Acta Derm Venereol. 2000;80:221.

    Article  PubMed  CAS  Google Scholar 

  43. De Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol. 2002;110:476–9.

    Article  PubMed  CAS  Google Scholar 

  44. Simon HU, Plotz SG, Simon D, et al. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol. 2001;124(1–3):242–5.

    Article  PubMed  CAS  Google Scholar 

  45. O’Shea JJ, Jaffe ES, Lane HC, et al. Peripheral T cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. Am J Med. 1987;82(3):539–45.

    Article  PubMed  Google Scholar 

  46. Moraillon I, Bagot M, Bourneriaas I, et al. Hypereosinophilic syndrome with pachyderma preceding lymphoma. Treatment with interferon alpha. Acta Derm Venereol. 1991;118(11):883–5.

    CAS  Google Scholar 

  47. Kim CJ, Park SH, Chi JG. Idiopathic hypereosinophilic syndrome terminating as disseminated T-cell lymphoma. Cancer. 1991;67(4):1064–9.

    Article  PubMed  CAS  Google Scholar 

  48. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291–300.

    Article  PubMed  CAS  Google Scholar 

  49. Fauci AS, Harley JB, Roberts WC, et al. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic and therapeutic considerations. Ann Intern Med. 1982;97(1):78–91.

    PubMed  CAS  Google Scholar 

  50. Parillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167–72.

    Google Scholar 

  51. Kazmierowski JA, Chusid MJ, Parillo JE, et al. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol. 1978;114:531–5.

    Article  PubMed  CAS  Google Scholar 

  52. Shelley WB, Shelley ED. Erythema annulare centrifugum as the presenting sign of the hypereosinophilic syndrome. Cutis. 1985;35:53–8.

    PubMed  CAS  Google Scholar 

  53. Milijkovic J, Bartenev I. Hypereosinophilic dermatitis-like erythema annulare centrifugum in a patient with chronic lymphocytic leukaemia. J Eur Acad Dermatol Venereol. 2005;19(2):228–31.

    Article  Google Scholar 

  54. Ohtani T, Okamoto K, Kaminaka C, et al. Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute (CDS). Eur J Dermatol. 2004;14(3):168–71.

    PubMed  Google Scholar 

  55. Jang KA, Lim YS, Cchoi JH, et al. Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud’s phenomenon complicated by digital gangrene. Br J Dermatol. 2000;143(3):641–4.

    Article  PubMed  CAS  Google Scholar 

  56. Bogenrieder T, Griese DP, Schiffner R, et al. Well’s syndrome as a manifestation of hypereosinophilic syndrome. Br J Dermatol. 1997;137(6):978–82.

    Article  PubMed  CAS  Google Scholar 

  57. Tsuji Y, Kawashima T, Yokota K, et al. Well’s syndrome as a manifestation of hypereosinophilic syndrome. Br J Dermatol. 2002;147(4):811–2.

    Article  PubMed  CAS  Google Scholar 

  58. Plötz SG, Abeck D, Behrendt H, et al. Eosinophilic cellulitis (Wells syndrome). Hautarzt. 2000;51(3):182–6.

    Article  PubMed  Google Scholar 

  59. Butterfield JH, Leifermann KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992;79:688–92.

    PubMed  CAS  Google Scholar 

  60. Banerji A, Weller PF, Sheikh J. Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich’s syndrome). Immunol Allergy Clin North Am. 2006;26(4):769–81.

    Article  PubMed  Google Scholar 

  61. Leiferman KM, Loegering DA, Gleich GJ. Production of wheal-and-flare skin reactions by eosinophil granule proteins. J Invest Dermatol. 1984;82:414.

    Google Scholar 

  62. Leiferman KM, Peter MS. Eosinophils in cutaneous diseases. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffel DJ, editors. Fitzpatrick’s dermatology in general medicine, 7th ed, Chap 35. New York Chicago: McGraw-Hill, Inc.; 2008.

  63. Jacyk WK, Simson LW, Slater DN, Leiferman KM. Pachydermatous eosinophilic dermatitis. Br J Dermatol. 1996;134:474–4698.

    Article  Google Scholar 

  64. Plötz SG, Simon HU, Ring J. Hautmanifestationen bei Hypereosinophiliesyndrom. Allergologie. 1998;21:489–98.

    Google Scholar 

  65. Plötz SG, Abeck D, Hein R, Ring J. High-dose UVA1 for hypereosinophilic syndrome. Arch Dermatol Res. 1998;290:81.

    Google Scholar 

  66. Butterfield JH, Gleich GJ. Interferon alpha treatment of six patients with the idiopathic hypereosinophilic syndromes. Ann Intern Med. 1994;121(9):648–53.

    PubMed  CAS  Google Scholar 

  67. Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1988;46(5):570–1.

    Article  PubMed  CAS  Google Scholar 

  68. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734–42.

    Article  PubMed  CAS  Google Scholar 

  69. Rotoli B, Catalano L, Galderisi M, et al. Rapid reversion of Loeffler’s endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma. 2004;45(12):2503–7.

    Article  PubMed  CAS  Google Scholar 

  70. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102(1):109–14.

    PubMed  CAS  Google Scholar 

  71. Monaco S, Lucci B, Laperchia N, et al. Polyneuropathy in hypereosinophilic syndrome. Neurology. 1988;38(3):494–6.

    PubMed  CAS  Google Scholar 

  72. Lefebvre C, Bletry O, Degoulet P, et al. Facteurs pronostiques du syndrome hypereosinophilique. Etude de 40 observations. Ann Med Interne (Paris). 1989;140:253–7.

    CAS  Google Scholar 

  73. Cordier JF, Faure M, Hermier C, Brune J. Pleural effusions in an overlap syndrome of idiopathic hypereosinophilic syndrome and erythema elevatum diutinum. Eur Respir J. 1990;3(1):115–8.

    PubMed  CAS  Google Scholar 

  74. Levesque H, Elie-Legrand MC, Thorel JM, et al. Idiopathic hypereosinophilic syndrome with predominant digestive manifestations or eosinophilic gastroenteritis? a propos of 2 cases. Gastroenterol Clin Biol. 1990;14(6–7):586–8.

    PubMed  CAS  Google Scholar 

  75. Scheurlen M, Mork H, Weber P. Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis. J Clin Gastroenterol. 1992;14(1):59–63.

    Article  PubMed  CAS  Google Scholar 

  76. Croffy B, Kopelman R, Kaplan M. Hypereosinophilic syndrome. Association with chronic active hepatitis. Dig Dis Sci. 1988;33(2):233–9.

    Article  PubMed  CAS  Google Scholar 

  77. Elouaer-Blanc L, Zafrani ES, Farcet JP, et al. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. Arch Intern Med. 1985;145(4):751–3.

    Article  PubMed  CAS  Google Scholar 

  78. Eugene C, Gury B, Bergue A, Quevauvilliers J. Icterus disclosing pancreatic involvement in idiopathic hypereosinophilic syndrome. Gastroenterol Clin Biol. 1984;8(12):966–9.

    PubMed  CAS  Google Scholar 

  79. Chaine G, Davies J, Kohner EM, et al. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Opthalmology. 1982;89(12):1348–56.

    CAS  Google Scholar 

  80. Binaghi M, Perrenoud F, Dhermy P, et al. Hypereosinophilic syndrome with ocular involvement. J Fr Opthalmol. 1985;8(4):309–14.

    CAS  Google Scholar 

  81. Takekawa M, Imai K, Adachi M, et al. Hypereosinophilic syndrome accompanied with necrosis of finger tips. Intern Med. 1992;31:1262–6.

    Article  PubMed  CAS  Google Scholar 

  82. Trueb RM, Lubbe J, Torricelli R, et al. Eosinophilic myositis with eosinophilic cellulitis like skin lesions. Association with increased serum levels of eosinophil cationic proteins and interleukin-5. Arch Dermatol. 1997;133:203–6.

    Article  PubMed  CAS  Google Scholar 

  83. Trueb RM, Pericin M, Winzeler B, et al. Eosinophilic myositis/perimyositis: frequence and spectrum of cutaneous manifestations. J Am Acad Dermatol. 1997;37:385–91.

    Article  PubMed  CAS  Google Scholar 

  84. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome II: clinical manifestations. Blood. 1991;58:1021–6.

    Google Scholar 

  85. Flaum MA, Schooley RT, Fauce AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Blood. 1981;58(5):1012–20.

    PubMed  CAS  Google Scholar 

  86. Brugnoni D, Airo P, Rossi G, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3− CD4+ T-cell population able to secrete large amounts of Interleukin-5. Blood. 1996;87:1416–22.

    PubMed  CAS  Google Scholar 

  87. Busse WW, Ring J, Huss-Marp J, Kahn E. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. JACI. 2010;125(4):803–13.

    CAS  Google Scholar 

  88. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109(11):4635–40.

    Article  PubMed  CAS  Google Scholar 

  89. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–25.

    Article  PubMed  CAS  Google Scholar 

  90. Chikama R, Hosokawa M, Miyazawa T, et al. Nonepisodic angioedema associated with eosinophilia. Report of 4 cases and review of 33 young female patients reported in Japan. Dermatology. 1998;197:321–5.

    Article  PubMed  CAS  Google Scholar 

  91. Spigel T, Winkelmann RK. Wells’ syndrome. Arch Dermatol. 1979;115:611–3.

    Article  PubMed  CAS  Google Scholar 

  92. Kamani N, Lipsitz PJ. Eosinophilic cellulitis in a family. Pediatr Dermatol. 1987;4:220–4.

    Article  PubMed  CAS  Google Scholar 

  93. Peters MS, Schroeter AL, Gleich GJ. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells’ syndrome. Br J Dermatol. 1983;109:141–8.

    Article  PubMed  CAS  Google Scholar 

  94. Yagi H, Tokura Y, Matsushita K, et al. Well’s syndrome: a pathogenetic role for circulating CD4 + CD7− T-cells expressing Interleukin-5 mRNA. Br J Dermatol. 1997;136:918–23.

    Article  PubMed  CAS  Google Scholar 

  95. Nir MA, Westfried M. Hypereosinophilic dermatitis. A distinct manifestation of the hypereosinopilie syndrome with response to dapsone. Dermatology. 1981;162:444–50.

    Article  CAS  Google Scholar 

  96. Schmelas A, Drobnitsch I, Schneider I. Hypereosinophilic dermatitis with response to ketotifen and sulfone. Dermatol Monatsschr. 1986;172(7):397–402.

    PubMed  CAS  Google Scholar 

  97. Butterfield JH, Leifermann KM, Gleich GJ. Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): a novel eosinophilic disorder. Clin Exp Allergy. 1993;23:571–80.

    Article  PubMed  CAS  Google Scholar 

  98. Pardanani A, Brockman SF, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104(10):3038–45.

    Article  PubMed  CAS  Google Scholar 

  99. Kimura T, Yoshimura S, Ishikawa E. Unusual granulation combined with hyperplastic changes in lymphatic tissue. Trans Jpn Soc Pathol. 1948;13:179–80.

    Google Scholar 

  100. Kung IT, Gibson JB, Bannatyne PM. Kimura’s disease: a clinicopathological study of 21 cases and its distinction from angiolymphoid hyperplasia with eosinophilia. Pathology. 1984;16(1):39–44.

    Article  PubMed  CAS  Google Scholar 

  101. Wang TF, Liu SH, Kao CH, et al. Kimura’s disease with generalized lymphadenopathy demonstrated by positron emission topography scan. Intern Med. 2006;45(12):775–8.

    Article  PubMed  Google Scholar 

  102. Chun SI. Kimura’s disease and ALHE with eosinophilia. J Am Acad Dermatol. 1992;27:954.

    Article  PubMed  CAS  Google Scholar 

  103. Conelly A, Powell HR, Chan YF, et al. Vincristine treatment of nephrotic syndrome complicated by Kimura’s disease. Pediatr Nephrol. 2005;20(4):516–8.

    Article  Google Scholar 

  104. Braun-Falco M, Fischer S, Plotz SG, Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol. 2004;151(5):1103–4.

    Article  PubMed  CAS  Google Scholar 

  105. Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:551–60.

    Article  PubMed  Google Scholar 

  106. Simon HU, Cools J. Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:519–27.

    Article  PubMed  Google Scholar 

  107. Klion AD, How I. treat hypereosinophilic syndromes. Blood. 2009;114:3736–41.

    Article  PubMed  CAS  Google Scholar 

  108. Gleich GJ, Leifermann KM. The hypereosinophilic syndromes: current concepts and treatments. Br J Hematol. 2009;145:271–85.

    Article  Google Scholar 

  109. Van den Hoogenband HM, van den Berg WH, van Diggelson MW. PUVA-therapy in the treatment of skin lesions of the hypereosinophilic syndrome. Clin Exp Dermatol. 1985;7:267–72.

    Article  Google Scholar 

  110. Eberlein A, von Kobyletzki G, Gruss C, et al. Erfolgreiche Monotherapie der hypreosinophilen Dermatitis mit PUVA-Bad-Photochemotherapie. Hautarzt. 1997;11:820–43.

    Article  Google Scholar 

  111. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826–7.

    Article  PubMed  CAS  Google Scholar 

  112. Zielinski RM, Lawrence WD. Interferon alpha for the hypereosinophilic syndrome. Ann Intern Med. 1990;113:716–8.

    PubMed  CAS  Google Scholar 

  113. Sefcick A, Sowter D, Da Gupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol. 2004;124:558–9.

    Article  PubMed  CAS  Google Scholar 

  114. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009;15(1):268–73.

    Article  Google Scholar 

  115. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 therapy for eosinophilic diseases. Hautarzt. 2007;122:124–7.

    Google Scholar 

  116. Leckie MF, ten Brinke A, Khan J, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2149–53.

    Article  PubMed  Google Scholar 

  117. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693–6.

    Article  PubMed  CAS  Google Scholar 

  118. Kay AB, Klion AD. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2004;114:1449–55.

    Google Scholar 

  119. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood. 2007;110:3552–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergology am Biederstein, Technical University Munich (TUM), Biedersteinerstr. 29, 80802, Munich, Germany

    Sabine Gisela Plötz, Bettina Hüttig, Christian Merkel, Knut Brockow, Ulf Darsow & Johannes Ring

  2. Dermatology Munich-Harlaching, Grünwalderstr. 248, 81545, Munich, Germany

    Sabine Gisela Plötz & Birgit Aigner

  3. Swiss Institute for Allergy and Asthma Research (SIAF), Davos, Switzerland

    Cezmi Akdis

  4. Christine Kühne Center for Allergy Research, Education (CK-CARE), Technical University Munich, Biedersteinerstr. 29, 80802, Munich, Germany

    Johannes Ring

Authors
  1. Sabine Gisela Plötz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bettina Hüttig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Birgit Aigner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Merkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Knut Brockow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cezmi Akdis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulf Darsow
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Johannes Ring
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Ring.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plötz, S.G., Hüttig, B., Aigner, B. et al. Clinical Overview of Cutaneous Features in Hypereosinophilic Syndrome. Curr Allergy Asthma Rep 12, 85–98 (2012). https://doi.org/10.1007/s11882-012-0241-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-012-0241-z

Keywords

Search

Navigation